Vulvovaginal Candidiasis Treatment Global Market Report 2025

The vulvovaginal candidiasis treatment market size has grown strongly in recent years. It will grow from $1.13 billion in 2024 to $1.19 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the rising prevalence of vulvovaginal candidiasis, the expansion of insurance coverage, the increasing number of clinical trials, advancements in research and development activities, and the growing use of broad-spectrum antibiotics.

The vulvovaginal candidiasis treatment market size is expected to see strong growth in the next few years. It will grow to $1.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period can be linked to rising healthcare expenditures, an expanding geriatric population, a higher prevalence of chronic diseases, the development of new antifungal medications, and increasing awareness of vaginal disorders. Key trends during this period include technological advancements, strategic collaborations, increased investment in research and development, innovative treatment options, and advanced therapies.

The increasing awareness of vaginal disorders is expected to drive the growth of the vulvovaginal candidiasis treatment market. Vaginal disorders encompass conditions that affect the vagina, including infections, inflammation, irritation, and abnormal discharge. This growing awareness is fueled by enhanced education, better healthcare access, and a stronger emphasis on women's health and well-being. Treatments for vulvovaginal candidiasis help patients by relieving symptoms such as itching, irritation, and abnormal discharge, restoring the vaginal microbiome, preventing recurrent infections, and improving overall vaginal health and comfort. For example, in October 2024, Cancer Australia, a government agency based in Australia, reported an estimated 123 new cases of vaginal cancer diagnosed in 2022, with 30 fatalities. As a result, the rising awareness of vaginal disorders is contributing to the expansion of the vulvovaginal candidiasis treatment market.

Leading companies in the vulvovaginal candidiasis treatment market are focusing on novel pharmaceuticals, such as oral and non-azole medications, to enhance treatment effectiveness and patient convenience. Oral and non-azole medication refers to antifungal drugs that are taken orally and do not belong to the azole class, providing an alternative treatment for fungal infections. For instance, in December 2022, Scynexis Inc., a US-based biotechnology company, introduced BREXAFEMME (ibrexafungerp tablets), an oral and non-azole medication, to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC). This medication was approved by the Food and Drug Administration (FDA), a US-based government agency, and became the first and only FDA-approved therapy for both treating vulvovaginal candidiasis (VVC) and lowering the incidence of recurrent VVC. This approval establishes BREXAFEMME as a crucial treatment option for patients with recurrent infections, offering a new approach to managing RVVC.

In February 2024, Mycovia Pharmaceuticals Inc., a US-based pharmaceutical company, partnered with Jiangsu Hengrui Pharmaceuticals Co. Ltd. to introduce VIVJOA (oteseconazole) capsules in China for the treatment of severe vulvovaginal candidiasis (VVC). Through this collaboration, Mycovia Pharmaceuticals Inc. and Jiangsu Hengrui Pharmaceuticals Co. Ltd. seek to provide an effective solution for severe vulvovaginal candidiasis, addressing patients' unmet medical needs and expanding therapeutic options for long-term fungal infection management. Jiangsu Hengrui Pharmaceuticals Co. Ltd. is a China-based company that specializes in treatments for vulvovaginal candidiasis.

Major players in the vulvovaginal candidiasis treatment market are Pfizer Inc., Bayer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences, Novartis Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Shandong Boyuan Pharmaceutical, Taro Pharmaceuticals Industries Ltd., Accord Healthcare Ltd., Incepta Pharmaceuticals Ltd., Cosette Pharmaceuticals Inc., Crescent Pharma Ltd., Bhumi Pharmaceuticals, Cidara Therapeutics Inc., Avet Pharmaceuticals Inc., Austell Pharmaceuticals Ltd., Laboratoire Riva Inc., Cadila Pharmaceuticals.

North America was the largest region in the vulvovaginal candidiasis treatment market in 2024. The regions covered in vulvovaginal candidiasis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vulvovaginal candidiasis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Vulvovaginal candidiasis treatment involves the medical management of a common fungal infection caused by Candida species, which affects the vaginal region. The goal of treatment is to ease symptoms such as itching, burning, and unusual discharge. These treatments primarily focus on reducing discomfort, restoring balance, and preventing the infection from recurring.

The primary medications used for vulvovaginal candidiasis include clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others. Clotrimazole, a widely used antifungal drug, is commonly prescribed for this condition. It can be administered orally, intravenously, or topically and is available through hospital pharmacies, retail pharmacies, and online pharmacies.

The vulvovaginal candidiasis treatment market research report is one of a series of new reports that provides vulvovaginal candidiasis treatment market statistics, including vulvovaginal candidiasis treatment industry global market size, regional shares, competitors with a vulvovaginal candidiasis treatment market share, detailed vulvovaginal candidiasis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the vulvovaginal candidiasis treatment industry. This vulvovaginal candidiasis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vulvovaginal candidiasis treatment market consists of sales of antifungal creams, oral antifungal capsules, suppositories, vaginal gels, pessaries, and non-azole medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.